Can Improved Use of Biomarkers Alter the Fate of PI3K Pathway Inhibitors in the Clinic?
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
received:
06
07
2021
revised:
01
09
2021
accepted:
27
09
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
7
1
2022
Statut:
ppublish
Résumé
The high frequency of PI3K pathway alterations in cancer has motivated numerous efforts to develop drugs targeting this network. Although many potent and selective inhibitors have been developed and evaluated in preclinical models, their progress to clinical approval has been limited. Here we discuss the pressing need to develop improved biomarker strategies to guide patient selection and improve assessment of patient responses to PI3K pathway inhibitors to address unresolved issues surrounding the efficacy and tolerability of these compounds in patients with cancer.
Identifiants
pubmed: 34911776
pii: 81/24/6083
doi: 10.1158/0008-5472.CAN-21-2035
pmc: PMC8738958
mid: NIHMS1748876
doi:
Substances chimiques
Biomarkers, Tumor
0
Phosphoinositide-3 Kinase Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
6083-6086Subventions
Organisme : NCI NIH HHS
ID : F31 CA254000
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA253097
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Cancer Discov. 2019 Apr;9(4):482-491
pubmed: 30867161
Curr Oncol Rep. 2019 Dec 11;21(12):110
pubmed: 31828441
Ther Clin Risk Manag. 2021 Mar 05;17:193-207
pubmed: 33707948
J Clin Oncol. 2016 Nov 1;34(31):3803-3815
pubmed: 27621407
Transl Oncogenomics. 2016 Feb 21;7(Suppl 1):33-49
pubmed: 26917948
Ann Oncol. 2019 Dec 1;30(Suppl_10):x27-x42
pubmed: 31859350
Methods Enzymol. 2007;434:117-30
pubmed: 17954245
J Clin Oncol. 2014 Apr 20;32(12):1202-9
pubmed: 24663045